ライフサイエンスコーパス: nonvalvular

1 4 patients with newly diagnosed (</=6 weeks) nonvalvular AF and >/=1 additional investigator-defined

2 0, 2014, we identified 655,000 patients with nonvalvular AF and a CHA2DS2-VASc score of >1 in the Nat

3 nducted at 59 hospitals of 707 patients with nonvalvular AF and at least 1 additional stroke risk fac

4 8,962 eligible individuals, 5,912 (66%) had nonvalvular AF and available eGFR data.

5 Patients diagnosed with nonvalvular AF and available estimated glomerular filtra

6 ith the Watchman device in 150 patients with nonvalvular AF and CHADS(2) (congestive heart failure, h

7 n Atrial Fibrillation), 14 264 patients with nonvalvular AF and creatinine clearance >/=30 mL/min wer

8 for patients on hemodialysis with new-onset nonvalvular AF and matched subjects without arrhythmia.

9 Patients aged 65 years or older with nonvalvular AF and risk factors for stroke (CHADS score

10 and systemic embolic events in patients with nonvalvular AF as effectively as well-controlled, adjust

11 r 3.8 years of follow-up among patients with nonvalvular AF at elevated risk for stroke, percutaneous

12 In patients aged 65 years or older with nonvalvular AF at increased risk for stroke (CHADS score

13 In patients with nonvalvular AF at moderate to high risk of stroke, impai

14 ) for stroke risk reduction in patients with nonvalvular AF at multiple time points over a lifetime h

15 Patients with nonvalvular AF at risk for stroke treated with left atri

16 ministration, patients with newly diagnosed, nonvalvular AF between 2004 and 2012 were identified who

17 patients starting warfarin therapy owing to nonvalvular AF during the study period were monitored un

18 , we identified all patients discharged with nonvalvular AF from 1997 to 2011.

19 edictors of thromboembolism in patients with nonvalvular AF have been identified, but their mechanist

20 zed controlled trials enrolled patients with nonvalvular AF not treated with oral anticoagulants.

21 From nonvalvular AF patients (n = 154,259), we identified 11,

22 gistries were used to identify patients with nonvalvular AF patients with or without concomitant HF.

23 we identified patients with newly diagnosed, nonvalvular AF seen within 90 days in an outpatient sett

24 , the authors identified 9,769 patients with nonvalvular AF who started taking an oral anticoagulant

25 individual data from 2580 participants with nonvalvular AF who were prescribed aspirin in a multicen

26 m a large global population of patients with nonvalvular AF, we sought to identify any differences in

27 se of the CHA2DS2-VASc stroke risk score for nonvalvular AF, with oral anticoagulation recommended fo

28 f DOAC availability on overall OAC rates for nonvalvular AF.

29 m, and cardiovascular death in patients with nonvalvular AF.

30 ention is no different in men and women with nonvalvular AF.

31 on) trial demonstrated that in patients with nonvalvular atrial fibrillation (AF) and CHADS2 (congest

32 cy of left atrial appendage (LAA) closure in nonvalvular atrial fibrillation (AF) patients ineligible

33 arin for stroke prophylaxis in patients with nonvalvular atrial fibrillation (AF).

34 Among 91330 patients with nonvalvular atrial fibrillation (mean age, 74.7 years [S

35 Stented subjects with nonvalvular atrial fibrillation (n=2124) were randomized

36 reduces the risk of stroke in patients with nonvalvular atrial fibrillation (NVAF) but increases the

37 unction is associated with increased risk of nonvalvular atrial fibrillation (NVAF) in older adults w

38 f acute kidney injury (AKI) in patients with nonvalvular atrial fibrillation (NVAF) remains unknown.

39 stemic embolism, and cardiovascular death in nonvalvular atrial fibrillation (NVAF) requires continue

40 illation) trial that evaluated patients with nonvalvular atrial fibrillation (NVAF), left atrial appe

41 oembolic risk, particularly in patients with nonvalvular atrial fibrillation (NVAF).

42 efficacy and safety outcomes in Asians with nonvalvular atrial fibrillation (NVAF).

43 al, Minneapolis, Minnesota) in patients with nonvalvular atrial fibrillation and absolute contraindic

44 Patients (n=707) with nonvalvular atrial fibrillation and at least 1 risk fact

45 Cs compared with VKAs to treat patients with nonvalvular atrial fibrillation and concomitant aspirin

46 t the analyses to those newly diagnosed with nonvalvular atrial fibrillation and naive-to-treatment,

47 was a man age 69 years with newly diagnosed nonvalvular atrial fibrillation and no contraindications

48 Of 11082 patients with nonvalvular atrial fibrillation and no known contraindic

49 Patients with nonvalvular atrial fibrillation are at increased risk of

50 bigatran versus warfarin in the treatment of nonvalvular atrial fibrillation are lacking.

51 In patients with nonvalvular atrial fibrillation at high risk of cardioem

52 to dabigatran and warfarin in patients with nonvalvular atrial fibrillation at risk for stroke witho

53 as the first-choice therapy in patients with nonvalvular atrial fibrillation because these drugs have

54 harged from the hospital with a diagnosis of nonvalvular atrial fibrillation between 1997 and 2008.

55 ated dabigatran or warfarin for treatment of nonvalvular atrial fibrillation between October 2010 and

56 ool in reducing stroke risk in patients with nonvalvular atrial fibrillation but is underused.

57 with Watchman provides stroke prevention in nonvalvular atrial fibrillation comparable to warfarin,

58 ith VKA in anticoagulant-naive patients with nonvalvular atrial fibrillation during the early phase o

59 ischemic strokes and emboli in patients with nonvalvular atrial fibrillation from 4.5% to 1.4% per ye

60 Patients with nonvalvular atrial fibrillation have a 4- to 5-fold incr

61 Strategies in patients with nonvalvular atrial fibrillation have included anticoagul

62 Patients diagnosed with nonvalvular atrial fibrillation in a 4-hospital institut

63 dabigatran versus warfarin for treatment of nonvalvular atrial fibrillation in general practice sett

64 Nonvalvular atrial fibrillation is a major cause of thro

65 Nonvalvular atrial fibrillation is common in elderly pat

66 rect oral anticoagulants among patients with nonvalvular atrial fibrillation is not known.

67 Nonvalvular atrial fibrillation is the most common arrhy

68 ith dabigatran and warfarin in patients with nonvalvular atrial fibrillation is unknown.

69 Physicians managing patients with nonvalvular atrial fibrillation must consider the risks,

70 trospective cohort study of 1876 adults with nonvalvular atrial fibrillation or flutter seen in prima

71 We included 6022 nonvalvular atrial fibrillation patients from 912 center

72 Among nonvalvular atrial fibrillation patients treated with da

73 compare persistence rates in newly diagnosed nonvalvular atrial fibrillation patients treated with wa

74 A total of 52 patients with nonvalvular atrial fibrillation underwent LAAC with the

75 tran prescriptions between 2010 and 2012 for nonvalvular atrial fibrillation were sampled (4863 total

76 e an alternative treatment for patients with nonvalvular atrial fibrillation who are less than optima

77 We randomly assigned 2124 participants with nonvalvular atrial fibrillation who had undergone PCI wi

78 tionwide cohort study included patients with nonvalvular atrial fibrillation who initiated dabigatran

79 e database and including 91330 patients with nonvalvular atrial fibrillation who received at least 1

80 l, we randomly assigned 14,264 patients with nonvalvular atrial fibrillation who were at increased ri

81 ied 39,400 patients discharged with incident nonvalvular atrial fibrillation with 0 or 1 CHA2DS2-VASc

82 United States is indicated in patients with nonvalvular atrial fibrillation with acceptable anatomy

83 Of 13,559 adults with nonvalvular atrial fibrillation, 11,526 were studied, 43

84 Among patients with nonvalvular atrial fibrillation, anticoagulation that re

85 e-dummy study of rivaroxaban and warfarin in nonvalvular atrial fibrillation, baseline characteristic

86 n preventing stroke and systemic embolism in nonvalvular atrial fibrillation, but has not been evalua

87 ally reduces the risk for ischemic stroke in nonvalvular atrial fibrillation, but its use among ambul

88 be cost-effective for typical patients with nonvalvular atrial fibrillation, but may be cost-effecti

89 Among patients taking NOACs for nonvalvular atrial fibrillation, concurrent use of amiod

90 hed data of patients >/=18 years of age with nonvalvular atrial fibrillation, randomized to either VK

91 on alternative to warfarin for patients with nonvalvular atrial fibrillation.

92 strokes in a cohort of 13,559 patients with nonvalvular atrial fibrillation.

93 n patients with mechanical cardiac valves or nonvalvular atrial fibrillation.

94 e initial management strategy for persistent nonvalvular atrial fibrillation.

95 dent than in the management of patients with nonvalvular atrial fibrillation.

96 and risk of major bleeding in patients with nonvalvular atrial fibrillation.

97 farin for stroke prevention in patients with nonvalvular atrial fibrillation.

98 ly INR-stable warfarin-treated patients with nonvalvular atrial fibrillation.

99 eventing ischemic stroke among patients with nonvalvular atrial fibrillation.

100 uperior to warfarin for stroke prevention in nonvalvular atrial fibrillation.

101 oral anticoagulants or VKA in patients with nonvalvular atrial fibrillation.

102 pared with warfarin in elderly patients with nonvalvular atrial fibrillation.

103 icant thromboembolic events in patients with nonvalvular atrial fibrillation.

104 g in the 110-mg dose in 18 113 patients with nonvalvular atrial fibrillation.

105 rials comparing VKAs and NOACs (n=71 681) in nonvalvular atrial fibrillation.

106 with warfarin for patients at risk who have nonvalvular atrial fibrillation.

107 duced intracranial bleeding in patients with nonvalvular atrial fibrillation.

108 or stroke prevention in 18 113 patients with nonvalvular atrial fibrillation.

109 7%) had heart failure, and 2,786 (19.3%) had nonvalvular atrial fibrillation.

110 d antithrombotic agents in patients who have nonvalvular atrial fibrillation.

111 lable to manage stroke risk in patients with nonvalvular atrial fibrillation; however, the cost-effec

112 association of biomarker or dietary ALA with nonvalvular CHF subtype.

113 uccessful biphasic electric cardioversion of nonvalvular persistent AF.

114 t valve procedure, and 45 (11.8%) concurrent nonvalvular procedures.